Invivyd (IVVD) Revenue & Revenue Breakdown
Invivyd Revenue Highlights
Invivyd Revenue by Period
Invivyd Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | - |
Invivyd generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Invivyd Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $3.02M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-09-30 | - | - |
Invivyd generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Invivyd Revenue Breakdown
Invivyd Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 24 |
|---|---|
| Product | $2.26M |
Invivyd's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (100.00%).
Invivyd Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RGNX | REGENXBIO | $90.24M | $22.30M |
| RXRX | Recursion Pharmaceuticals | $44.58M | $13.79M |
| EXAI | Exscientia | $24.96M | $5.29M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| GBIO | Generation Bio | $5.90M | $4.06M |
| ABEO | Abeona Therapeutics | $3.50M | - |
| MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| ERAS | Erasca | - | - |
| PASG | Passage Bio | - | - |
| APVO | Aptevo Therapeutics | - | - |
| UBX | Unity Bio | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| IVVD | Invivyd | - | - |
| AVIR | Atea Pharmaceuticals | - | - |
IVVD Revenue FAQ
What is Invivyd’s yearly revenue?
Invivyd's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. IVVD's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Invivyd’s quarterly revenue?
Invivyd's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $3.02M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). IVVD's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Invivyd’s revenue growth rate?
Invivyd's revenue growth rate for the last 3 years (2021-2023) was 0%